Sarepta Therapeutics Inc (SRPT)
Profitability ratios
Return on sales
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 62.22% | 58.71% | 54.60% | 54.37% | 49.41% | 51.26% | 53.23% | 55.63% | 62.32% | 58.99% | 54.17% | 49.08% | 46.47% | 41.02% | 36.59% | 30.24% | 24.46% | 24.99% | 26.47% | 28.58% |
| Operating profit margin | -6.76% | -21.54% | -36.13% | -50.81% | -60.20% | -57.47% | -61.09% | -52.48% | -51.55% | -65.50% | -81.26% | -104.52% | -104.30% | -104.46% | -125.97% | -135.54% | -183.36% | -185.27% | -168.35% | -162.87% |
| Pretax margin | 2.43% | -41.83% | -59.89% | -88.20% | -112.59% | -73.95% | -81.11% | -60.11% | -46.45% | -59.69% | -75.21% | -105.66% | -122.63% | -102.40% | -121.11% | -117.57% | -160.66% | -187.45% | -169.95% | -165.86% |
| Net profit margin | 1.20% | -43.11% | -62.52% | -90.46% | -114.30% | -75.40% | -81.76% | -60.66% | -46.56% | -59.66% | -75.30% | -105.73% | -122.77% | -102.60% | -121.30% | -117.80% | -160.96% | -187.77% | -169.87% | -165.52% |
Sarepta Therapeutics Inc's profitability ratios indicate varying levels of performance over the past few quarters.
- Gross profit margin has shown fluctuation but generally improved over the recent quarters, indicating the company's ability to control production costs and generate profit from sales.
- Operating profit margin has also fluctuated significantly, with some quarters showing negative margins. This suggests that the company is facing challenges in managing its operating expenses effectively.
- The pretax margin shows a similar trend to the operating margin, with significant fluctuations and negative margins in some quarters. This indicates that the company is struggling with expenses before accounting for taxes.
- The net profit margin has been consistently negative, signaling that the company's bottom line is not profitable after all expenses, including taxes, are accounted for. This could raise concerns about the overall profitability and sustainability of Sarepta Therapeutics Inc's business operations.
In conclusion, while there have been improvements in the gross profit margin, Sarepta Therapeutics Inc still faces significant challenges in controlling operating expenses and generating profits at the net level. Investors and stakeholders may need to closely monitor the company's performance to ensure sustainable profitability in the future.
Return on investment
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -2.94% | -8.20% | -12.84% | -16.31% | -19.20% | -17.14% | -16.96% | -14.62% | -12.92% | -14.60% | -19.71% | -22.73% | -21.63% | -18.90% | -22.43% | -21.16% | -25.35% | -38.71% | -36.11% | -32.11% |
| Return on assets (ROA) | 0.52% | -16.42% | -22.22% | -29.04% | -36.45% | -22.49% | -22.69% | -16.91% | -11.67% | -13.30% | -18.26% | -23.00% | -25.45% | -18.57% | -21.60% | -18.40% | -22.25% | -39.23% | -36.43% | -32.63% |
| Return on total capital | 2.57% | -25.01% | -31.90% | -43.10% | -54.17% | -33.00% | -32.83% | -23.98% | -14.93% | -17.55% | -26.80% | -36.12% | -39.41% | -28.11% | -34.53% | -27.98% | -33.71% | -45.54% | -41.28% | -35.21% |
| Return on equity (ROE) | 1.76% | -62.37% | -90.39% | -122.43% | -156.47% | -182.75% | -166.24% | -69.74% | -41.61% | -45.13% | -103.53% | -130.79% | -131.46% | -72.74% | -67.32% | -50.85% | -57.29% | -87.40% | -62.33% | -51.89% |
Sarepta Therapeutics Inc's profitability ratios have shown a fluctuating trend over the past few quarters.
- Operating return on assets (Operating ROA) has been consistently negative, indicating that the company is not efficiently utilizing its assets to generate operating profits.
- Return on assets (ROA) has also been negative, with a significant decline in the profitability ratio from the previous year, suggesting that the company's overall profitability in relation to its total assets has been deteriorating.
- Return on total capital has also displayed negative values, indicating that the company is not effectively generating returns on its total invested capital.
- Return on equity (ROE) has shown fluctuations with mostly negative values, highlighting the company's inability to generate satisfactory returns for its equity shareholders.
Overall, the profitability ratios of Sarepta Therapeutics Inc reflect challenges in profitability and efficiency in utilizing assets and capital to generate returns for investors.